Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1861 to 1875 of 7615 results

  1. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development [GID-TA11218] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development [GID-TA11100] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Leriglitazone for treating andrenoleukodystrophy [ID3903]

    In development [GID-TA11445] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    Awaiting development [GID-TA11367] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Awaiting development [GID-TA11406] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

    Technology appraisal guidance
    In development

  8. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    In development [GID-TA10596] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development [GID-TA10046] Expected publication date: 22 November 2017

    Technology appraisal guidance
    In development

  10. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development [GID-TA10966] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

    Awaiting development [GID-TA10198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095

    Awaiting development [GID-TA10993] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development [GID-TA10089] Expected publication date: 15 November 2017

    Technology appraisal guidance
    In development

  14. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development [GID-TA10605] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development [GID-TA11036] Expected publication date: TBC

    Technology appraisal guidance
    In development